IR-MED Inc

IR-Med, Inc. (OTCQB: IRME) is a development-stage medical device company headquartered in Rosh Pinna, Israel, focused on the development of non-invasive, artificial intelligence-driven diagnostic tools utilizing infrared spectroscopy and spectrographic analysis to address unmet clinical needs in point-of-care medicine. The company was founded in 2012 and became a fully SEC-reporting company in November 2021 when its resale registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission. IR-Med's technology platform combines infrared light spectroscopy — which analyzes how biological tissues absorb and reflect infrared light at specific wavelengths — with AI pattern recognition algorithms to generate diagnostic insights from tissue optical properties without requiring blood draws, biopsies, or other invasive procedures.<br><br>IR-Med's product pipeline includes three distinct medical device candidates targeting high-priority clinical needs. PressureSafe is a handheld optical monitoring device being developed to support the early detection of pressure injuries — wounds that develop when sustained pressure on skin and underlying tissue causes cellular damage in patients who are bedridden, wheelchair-bound, or otherwise immobile. DiaSafe is a companion handheld device being developed to support early detection of diabetic foot ulcers in the lower limb skin and underlying tissue of diabetic patients — a major complication of diabetes that can lead to severe infection and amputation if not identified early. Nobiotics is an AI-enhanced otoscope designed to help physicians immediately distinguish whether a middle ear infection is of bacterial or viral origin, enabling more targeted antibiotic prescribing.<br><br>IR-Med, Inc. trades on the OTCQB Venture Market under the ticker symbol IRME and files periodic reports with the Securities and Exchange Commission. All three of the company's device candidates remain in development, and the company has not yet generated product revenue, reflecting its pre-commercialization stage. The addressable clinical markets for pressure injury detection, diabetic foot ulcer prevention, and otitis media diagnosis are substantial globally, with pressure injuries alone affecting millions of hospitalized and long-term care patients annually and costing healthcare systems billions of dollars in treatment costs.